Shots:

• The 1st patient has been dosed in the P-III RSJ10333 trial to evaluate the safety and efficacy of SHR0302 (4mg/8mg- after the completion of 16 wks treatment) vs. PBO in 330 adolescent & adult aged ≥12 yrs with a mod. to sev. AD for 52 wks. The trial is being conducted in Canada & China while the 1st patients enrolled were from Canada
• The P-III program is based on results from the P-II study with both doses of SHR0302 vs PBO that showed improvement in reducing symptoms & lesion clearance. The results of the P-II study were presented at AAD VMX 2021
• SHR0302 is an orally administered- novel- potent & selective JAK1 inhibitor for the treatment of various autoimmune & inflammatory diseases

  Ref: PRNewswire| Image: Reistone Biopharma